CO6410293A2 - Nueva formula cristalina vi de la agomelatina preparación y uso de la misma - Google Patents

Nueva formula cristalina vi de la agomelatina preparación y uso de la misma

Info

Publication number
CO6410293A2
CO6410293A2 CO11109271A CO11109271A CO6410293A2 CO 6410293 A2 CO6410293 A2 CO 6410293A2 CO 11109271 A CO11109271 A CO 11109271A CO 11109271 A CO11109271 A CO 11109271A CO 6410293 A2 CO6410293 A2 CO 6410293A2
Authority
CO
Colombia
Prior art keywords
preparation
crystalline form
agomelatina
cristalina
same
Prior art date
Application number
CO11109271A
Other languages
English (en)
Inventor
Hanbn Shan
Peng Zhang
Xiong Yu
Xingdong Cheng
Xufeng Cao
Hubo Wang
Yu Huang
Xudong Jiang
Zhedong Yuan
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41370233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410293(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO6410293A2 publication Critical patent/CO6410293A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona una nueva forma cristalina de la agomelatina, la preparación y uso de ésta. El diagrama de difracción de rayos X en polvo de la forma cristalina de la agomelatina muestra picos principales en los ángulos de difracción 2? 11,13°, 11,82°, 17,49°, 18,29°, 19,48°, 19,72°, 20,50°, 21,76°, 22,54°, 22,97°, 24,56°, 25,36°, 27,16° y 31,93°. Dicha nueva forma cristalina se caracteriza por una alta pureza, estabilidad y buena reproducibilidad, y es así ventajosa para la formulación farmacéutica. Además, la estabilidad solubilidad de dicha forma cristalina también son superiores a las distintas formas cristalinas existentes.
CO11109271A 2009-03-10 2011-08-26 Nueva formula cristalina vi de la agomelatina preparación y uso de la misma CO6410293A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910047329.2A CN101585779B (zh) 2009-03-10 2009-03-10 阿戈美拉汀的晶型vi及其制备方法和应用

Publications (1)

Publication Number Publication Date
CO6410293A2 true CO6410293A2 (es) 2012-03-30

Family

ID=41370233

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11109271A CO6410293A2 (es) 2009-03-10 2011-08-26 Nueva formula cristalina vi de la agomelatina preparación y uso de la misma

Country Status (27)

Country Link
US (1) US8614251B2 (es)
EP (1) EP2431355A4 (es)
JP (1) JP2012519715A (es)
KR (1) KR20110123266A (es)
CN (1) CN101585779B (es)
AP (1) AP3049A (es)
AU (1) AU2010223720B2 (es)
BR (1) BRPI1013249A2 (es)
CA (1) CA2754276A1 (es)
CL (1) CL2011002231A1 (es)
CO (1) CO6410293A2 (es)
CR (1) CR20110457A (es)
CU (1) CU20110162A7 (es)
EA (1) EA019127B1 (es)
EC (1) ECSP11011309A (es)
GE (1) GEP20146114B (es)
HN (1) HN2011002408A (es)
IL (1) IL214683A0 (es)
MA (1) MA33100B1 (es)
MX (1) MX2011009339A (es)
NI (1) NI201100167A (es)
PE (1) PE20120653A1 (es)
SG (2) SG177886A1 (es)
TN (1) TN2011000426A1 (es)
UA (1) UA100476C2 (es)
WO (1) WO2010102554A1 (es)
ZA (1) ZA201106049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102557979B (zh) * 2010-12-16 2014-11-26 北大方正集团有限公司 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2771312B1 (en) 2011-11-30 2017-05-31 ratiopharm GmbH Agomelatine-urea complex and crystalline forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
ES2959460T3 (es) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine

Also Published As

Publication number Publication date
TN2011000426A1 (en) 2013-03-27
US20120004313A1 (en) 2012-01-05
CN101585779A (zh) 2009-11-25
GEP20146114B (en) 2014-07-10
EP2431355A4 (en) 2012-08-08
KR20110123266A (ko) 2011-11-14
CR20110457A (es) 2011-09-21
MA33100B1 (fr) 2012-03-01
EA201101304A1 (ru) 2012-04-30
ECSP11011309A (es) 2011-10-31
CU20110162A7 (es) 2012-02-15
CN101585779B (zh) 2014-04-02
ZA201106049B (en) 2012-10-31
JP2012519715A (ja) 2012-08-30
AP2011005914A0 (en) 2011-10-31
HN2011002408A (es) 2014-06-23
UA100476C2 (en) 2012-12-25
CL2011002231A1 (es) 2012-02-03
IL214683A0 (en) 2011-11-30
EA019127B1 (ru) 2014-01-30
BRPI1013249A2 (pt) 2016-04-05
EP2431355A1 (en) 2012-03-21
CA2754276A1 (en) 2010-09-16
NI201100167A (es) 2012-01-11
SG177886A1 (en) 2012-02-28
WO2010102554A1 (zh) 2010-09-16
AP3049A (en) 2014-11-30
PE20120653A1 (es) 2012-06-14
US8614251B2 (en) 2013-12-24
AU2010223720B2 (en) 2012-05-03
SG173692A1 (en) 2011-09-29
AU2010223720A1 (en) 2011-09-08
MX2011009339A (es) 2011-09-27

Similar Documents

Publication Publication Date Title
CO6410293A2 (es) Nueva formula cristalina vi de la agomelatina preparación y uso de la misma
AR096046A1 (es) Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
AR077242A1 (es) Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades.
NI201300103A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [ 2, 3-d] PIRIMIDINA TROPOMIOSINA
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
ECSP14004812A (es) Triazolopiridinas sustituidas
CO7170182A2 (es) Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
ECSP109910A (es) Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CU24100B1 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
AR070560A1 (es) Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471
ECSP12012338A (es) Triazolopiridinas sustituidas
BRPI0506858A (pt) composto, métodos de preparação de monoidrato de gaboxadol cristalino e de anidrato de gaboxadol cristalino, composição farmacêutica, e, uso de um composto
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
UY35275A (es) Derivados de aminopirazina
AR082601A1 (es) Formas cristalinas de compuestos de pirimido[6,1-a]isoquinolin-4-ona
RU2014104994A (ru) Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion

Legal Events

Date Code Title Description
FC Application refused